#United States #Kessler Topaz #Radnor #uniQure N.V. #AMT-130

Investigation into uniQure N.V. by Kessler Topaz Meltzer & Check, LLP

Recent developments have led to a significant downturn for investors of uniQure N.V. (NASDAQ: QURE). Kessler Topaz Meltzer & Check, LLP, a prominent law firm known for advocating on behalf of investors, is conducting an investigation concerning potential infringements of federal securities laws related to uniQure's actions.

On November 3, 2025, uniQure announced unsettling news that has prompted this legal examination. The company revealed that the FDA informed them that the data submitted for their investigational gene therapy, AMT-130, did not meet the necessary standards to support the submission of their Biologics License Application (BLA). This stemmed from the FDA's assertion that the clinical data from the Phase I/II studies did not provide sufficient evidence, which could undermine the approval of AMT-130 as a treatment for Huntington's disease.

As a direct result of this announcement, uniQure’s stock experienced a dramatic plunge, decreasing over 50%, dropping from a closing price of $67.69 on October 31, 2025, to just $34.29 by the end of the trading session on November 3, 2025. This abrupt decline has led to significant losses for numerous shareholders who trusted the company's potential in pioneering gene treatments.

Why the Investigation?

Kessler Topaz Meltzer & Check, LLP aims to ensure that investors are fully informed and protected. Their investigation seeks to uncover whether the disclosures made by uniQure were misleading or deficient, thereby causing investors to suffer financial setbacks. Investors who find themselves adversely affected are encouraged to reach out to Kessler Topaz Meltzer & Check, LLP to discuss their options and to participate in the investigation.

This firm's reputation precedes it, recognized for securing major recoveries in securities litigation. Representing a broad spectrum of clients—from individual stakeholders to institutional investors such as large pension funds and asset managers—Kessler Topaz is dedicated to safeguarding investor rights.

Should you have experienced significant financial loss due to the recent happenings surrounding uniQure, you have the option to connect with Kessler Topaz. Potential claimants are invited to fill out an online form or make direct contact with attorney Jonathan Naji at (484) 270-1453 or via email at email protected] Additionally, for further information, you can visit their website at [www.ktmc.com.

This investigation stands as a reminder of the responsibilities that biopharmaceutical companies hold towards their investors. Shareholders deserve transparent and accurate information regarding the viability and safety of medical therapies under development.

The stakes remain high within the biotech sector—especially concerning breakthrough treatments like AMT-130. However, with each milestone achieved, there are associated risks that must be carefully communicated to those providing financial backing.

As Kessler Topaz continues its inquiry, investors involved with uniQure are advised to stay tuned for updates and take proactive steps to assure their interests are well represented during this challenging time. This situation illustrates the critical nature of investor vigilance and the vital role law firms play in holding corporations accountable to their shareholders.

In conclusion, if you have suffered losses associated with uniQure’s stock, Kessler Topaz Meltzer & Check, LLP stands ready to assist you, ensuring that your voice is heard in the pursuit of justice and compensation.